A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations

Exclusion Criteria

• •Subjects who received an investigational agent \<14 days prior to their first day of study drug administration
• •Subjects who are pregnant or breastfeeding
• •Subjects with an active severe infection, some treated infections and with an expected or with an unexplained fever \>38.3°C during screening visits or on their first day of study drug administration.
• •Subjects with some current or prior heart conditions
• •Subjects taking medications that are known to prolong the QT interval may not be eligible
• •Subjects with immediately life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation
• •Some subjects with some current or prior gastrointestinal or liver diseases
• •Subjects with inadequate organ function as defined by the protocol